Our Board of Directors

Martha Goldberg Aronson

Martha Goldberg Aronson served as Executive Vice President and President-Global Healthcare, from September 2012 to November 2015 at Ecolab, Inc., a specialty chemical company. Prior to Ecolab, Ms. Goldberg Aronson served as Senior Vice President and President, North America, of Hill-Rom Holdings, Inc., a leading worldwide manufacturer and provider of medical technologies and related services for the health-care industry. Before joining Hill-Rom, she served as Senior Vice President at Medtronic, Inc., from March 2008 to November 2009, and in various other domestic and international general management positions with Medtronic throughout her 18 years at the company. She also serves as a director of Cardiovascular Systems Inc. and CONMED Corporation, where she is the Lead Independent Director. She previously served as a director of Hutchinson Technology, Methode Electronics and Clinical Innovations, LLC. Ms. Goldberg Aronson holds a BA degree in Economics from Wellesley College and an MBA degree from Harvard Business School.

Chair of the Board:

Beth A. Brooke

Director, eHealth, Beta Bionics, SHEEX, and The United States Olympic and Paralympic Committee (USOPC)

 

Beth Brooke serves on the Board of eHealth (NASDAQ:EHTH), Beta Bionics, and SHEEX, as well as The United States Olympic and Paralympic Committee (USOPC), Aspen Institute, Conference Board, Vital Voices, the Partnership for Global LGBT Equality, and APCO’s International Advisory Council. She chairs Audit, Strategy, and Regulatory committees.

 

Formerly, Brooke had a 4 decade career at EY, was its  Global Vice Chair-Public Policy, a member of EY’s Global Board, and global sponsor of Diversity and Inclusion.  In the Clinton Administration, she played roles in the Healthcare and Superfund reform efforts and had tax policy responsibility for insurance and managed care.

 

Brooke is a global advocate of diversity and inclusion for the LGBTcommunity and women, named to Forbes "World's 100 Most Powerful Women" list eleven times. She earned a B.S. degree in Industiral management and computer science from Purdue Universtiy where she played intercollegiate basketball.

Sean D. Carney

Sean Carney currently serves as a senior advisor with Hillhouse Capital. From 1996 to 2016, Mr. Carney was a Managing Director at Warburg Pincus, the global private equity firm. He has served on numerous public and private company boards, including Bausch + Lomb, Dexcom, Tornier, and Wright Medical. Prior to joining Warburg Pincus in 1996, Mr. Carney was a consultant with McKinsey & Company. Mr. Carney received an AB degree in economics from Harvard College and an MBA degree from Harvard Business School. 

Ed Damiano, PHD

Ed Damiano is a Professor of Biomedical Engineering at Boston University (BU), where he has held that role since 2004. His expertise and training are in the areas of mechanical and biomedical engineering and applied mechanics. Ever since his son was diagnosed with type 1 diabetes (T1D) at 11 months of age, he has been committed to creating and integrating closed-loop glycemic control technologies with a vision of building a bionic pancreas. This endeavor began with the design and development of mathematical algorithms to control blood glucose, which he and his team began testing in his laboratory at Boston University in 2005. These efforts led to the development of the iLet® bionic pancreas bionic pancreas. In 2015, Drs. Damiano and El-Khatib, along with Ed Raskin and Serafina Raskin, founded Beta Bionics, Inc. as a Massachusetts public benefit corporation with the goal of bringing the iLet bionic pancreas through clinical trials, regulatory clearance and into the hands of people with T1D.

Jeff Hitchcock

Jeff Hitchcock is the Founder and President of Children with Diabetes, an Ohio-based 501(c)(3) non-profit that provides education and support to families living with type 1 diabetes through its web site (www.childrenwithdiabetes.com) and conferences throughout the United States and, in partnership with other non-profit organizations, in Canada and the United Kingdom. Since founding Children with Diabetes in 1995, Mr. Hitchcock and Children with Diabetes have hosted almost 100 conferences and educational events focused on improving the lives of families living with diabetes.

Finny Kuruvilla, MD, PhD

Finny Kuruvilla is the Chief Investment Officer for Eventide Funds, Lead Portfolio Manager for the Eventide Gilead Fund, and Portfolio Manager for the Eventide Healthcare & Life Sciences Fund. Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with Eventide, from 2008 through 2016, he was a Principal at Clarus Ventures, a leading healthcare and life sciences venture capital firm. Prior to joining Eventide, from 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT, and from 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women’s Hospital and Children’s Hospital Boston and a postdoctoral scientist at MIT.  He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry.

Board Members:

Christian Foged

Corporate Project Vice President at Novo Nordisk

Deirdre Isben

Platform Leader, Diabetes Development at Eli Lilly and Company

Michael Pratt

Managing Director, Technology Development at Boston University

Adam Steensberg, MD

Executive Vice President, Chief Medical and Development Officer for Zealand Pharma 

Board Observers:

CAUTION: The iLet® bionic pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.

© 2021 Beta Bionics, Inc. Beta Bionics® and iLet® are registered trademarks of Beta Bionics, Inc. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.